Align Technology INC 8-K filings

Align Technology is enhancing its board with three new directors and launching a strategic review with a consulting firm to drive growth and shareholder value.

Align Technology announced record second quarter 2026 revenues of $1.06 billion, driven by strong Clear Aligner performance, while Systems and Services revenue saw a decline.

Align Technology, Inc. reported voting results from its 2026 Annual Meeting of Stockholders, including the election of directors and advisory votes on executive compensation.

Align Technology announced its first quarter 2026 financial results, reporting $1,040.1 million in total revenues, a 6.2% increase year-over-year, and reaffirming its fiscal 2026 guidance.

Align Technology, Inc. has adopted Amended and Restated Bylaws, notably revising the threshold for stockholders to call a special meeting to 25% of outstanding common stock held for at least one year.

Align Technology reported third-quarter 2025 revenues of $995.7 million, surpassing its guidance, driven by strong international Clear Aligner volume growth, particularly in teens and kids.

Align Technology announced the termination of employment for Stuart Hockridge, Executive Vice President of Global Human Resources, effective May 2026.

Align Technology announced plans to repurchase $200 million of its common stock, signaling management confidence and strong financial health.

Align Technology reported mixed second-quarter 2025 financial results, with revenues slightly down year-over-year and operating margins below outlook, prompting a strategic restructuring plan for the second half of 2025.

Align Technology, a leading global medical device company, announced the appointment of Britt Vitalone, Executive Vice President and CFO of McKesson Corporation, to its Board of Directors and Audit Committee, increasing the board size to eleven members.

Align Technology's stockholders approved an amendment to the 2005 Incentive Plan at the 2025 Annual Meeting, increasing the number of shares authorized for issuance.

Align Technology's Board of Directors has authorized a new $1 billion stock repurchase program and the company reiterated its prior financial guidance during its Investor Day.

Align Technology announces its first quarter 2025 financial results, highlighting a 6.2% year-over-year increase in Clear Aligner volume and celebrating the 20 million Invisalign patient milestone.

Align Technology plans to repurchase $225 million of its common stock, completing its previously announced $1 billion stock repurchase program.

Align Technology announced its Q4 and fiscal year 2024 results, showcasing revenue and volume growth, but also highlighting the impact of unfavorable foreign exchange rates.

Align Technology plans to repurchase $275 million of its common stock through open market transactions, reflecting confidence in its financial position and future growth.

Align Technology's Q3 2024 results show a slight revenue increase year-over-year, but were impacted by a soft US dental market and foreign exchange, leading to a restructuring plan and a stock repurchase program.

Align Technology's Q2 2024 results show a 2.6% year-over-year revenue increase to $1,028.5 million, with growth in both clear aligner volumes and imaging systems.

Align Technology announced the appointment of Emory Wright to lead direct fabrication manufacturing and the promotion of Srini Kaza to head research and development, alongside other executive changes.

Align Technology plans to repurchase $150 million of its common stock through open market transactions, signaling confidence in its financial position and future growth.

Align Technology's first quarter 2024 results show a 5.8% year-over-year revenue increase, fueled by growth in both clear aligners and imaging systems.

Align Technology announced better-than-expected fourth quarter and full year 2023 financial results, highlighted by the launch of the next-generation iTero Lumina intraoral scanner.

Align Technology's Board of Directors has approved and adopted an amendment and restatement of the company's bylaws, effective immediately, to align with the SEC's universal proxy rules and update various procedural mechanics.